ISSUE: 01 | 01.06.11
SAVING LIVES REQUIRES YOUR HELP.
Get educated and spread the word about the latest in prostate cancer treatments, research and clinical trials. ZEROHOUR, replaces Aware as ZERO's weekly report on ending
prostate cancer.
Late Stage Drug Reaches Expanded Access Program in Prep for FDA Review
Abiraterone will soon be available at clinical recruitment centers to treat patients with metastatic hormone therapy resistant prostate cancer who have progressed after taxane-based chemotherapy. Centers are currently recruiting in California, Connecticut, Florida, Georgia, Louisiana and New York.
Learn More About the Expanded Access Program (EAP)
Partnership Invests Millions in 'Liquid Biopsies'
A new experimental test could enable doctors detect cancer and tailor treatment based on a simple blood test that utilizes a plastic ship with microscopic inner surfaces covered in antibodies to grab cancer cells from the blood. Those cells can then be analyzed in detail to determine severity of the disease.
Click Here to Read the Full Article
Outlining the Treatment Options
The Washington Post consumer reports put together an outline of current prostate cancer treatments with what types of patients should be aware of them. The article calls for greater awareness as patients often choose aggressive treatments for good reasons, including reassurance. However, confusing information can bias decisions.
Click Here to Read the Full Article
112th Congress Opened This Week
More than 100 new members will be sworn into office in the House and Senate today as the 112th Congress opens. The first order of business will be adopting the new Rules of the House and likely filibuster reform in the Senate. In the coming weeks, besides the more news worthy topics such as repealing health care reform and reducing the federal deficit, the new Congress will have to deal with completing the discretionary spending package funding the government for the current fiscal year and beginning the funding process for fiscal year 2012 which begins October 1. That process will officially start in early February when the Administration transmits the President's budget proposal to Congress.
In addition to protecting funding for prostate cancer research in the current budget, we will focus our efforts to increase funding in FY2012.
Please write your Congressional delegation today to welcome them to the 112th Congress and ask for their support for increased research funding.
Write Your Congressional Delegate
Classifieds
Advertise in ZEROHOUR, ZERO's weekly electronic newsletter, to reach nearly 30,000 readers throughout the prostate cancer community in the U.S. and abroad. Contact Jamie Bearse at (202) 303-3105 to learn more about our advertising and partner development opportunities.
Download ZEROHOUR Ad Specs
   
|
